Does Rallies show Form 4 insider transactions for CLDX?

Yes. Rallies tracks CLDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CLDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLDX. It does not provide personalized investment advice.

CLDX (Celldex Therapeutics, Inc) Stock Analysis - Insider Trades

Celldex Therapeutics, Inc (CLDX) is a publicly traded Healthcare sector company. As of May 20, 2026, CLDX trades at $31.08 with a market cap of $2.37B and a P/E ratio of -7.83. CLDX moved +2.54% today. Year to date, CLDX is +20.70%; over the trailing twelve months it is +50.81%. Its 52-week range spans $14.40 to $35.79. Analyst consensus is strong buy with an average price target of $56.73. Rallies surfaces CLDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CLDX stock inside the company?

Recent CLDX insider activity includes Jimenez Freddy A. sold 4.17K, Wright Richard M. sold 49.30K, Jimenez Freddy A. sold 341, Jimenez Freddy A. sold 430, and Marucci Anthony S bought 11.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CLDX Key Metrics

Key financial metrics for CLDX
Metric	Value
Price	$31.08
Market Cap	$2.37B
P/E Ratio	-7.83
EPS	$-3.90
Dividend Yield	0.00%
52-Week High	$35.79
52-Week Low	$14.40
Volume	645.12K
Avg Volume	0
Revenue (TTM)	$1.54M
Net Income	$-258.76M
Gross Margin	87.06%

Recent CLDX Insider Trades

Jimenez Freddy A. sold 4.17K (~$121.21K) on Dec 4, 2025.
Wright Richard M. sold 49.30K (~$1.18M) on Nov 13, 2025.
Jimenez Freddy A. sold 341 (~$8.17K) on Aug 13, 2025.
Jimenez Freddy A. sold 430 (~$10.93K) on Aug 13, 2025.
Marucci Anthony S bought 11.50K (~$308.43K) on Nov 11, 2024.

Latest CLDX News

Celldex Raises $345M and Completes Phase 3 CSU Enrollment Six Months Early — May 7, 2026
Celldex Launches Stock Offering with 15% Overallotment Option — Apr 1, 2026
Celldex Barzolvolimab Achieves 71% CSU Response, 66% ColdU Complete Rate — Mar 27, 2026
Celldex Reports $121K Revenue Miss, -$1.22 EPS and 13.01 Current Ratio — Feb 26, 2026
Celldex Finishes Enrollment Six Months Early in 1,939-Patient Phase 3 CSU Trials — Feb 25, 2026

CLDX Analyst Consensus

12 analysts cover CLDX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $56.73.

Common questions about CLDX

Who is trading CLDX stock inside the company?: Recent CLDX insider activity includes Jimenez Freddy A. sold 4.17K, Wright Richard M. sold 49.30K, Jimenez Freddy A. sold 341, Jimenez Freddy A. sold 430, and Marucci Anthony S bought 11.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CLDX?: Yes. Rallies tracks CLDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CLDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLDX. It does not provide personalized investment advice.